1,520 results on '"Germing, U"'
Search Results
2. Response-guided first-line therapy and treatment of relapse in aggressive lymphoma: 10-year follow-up of the PETAL trial
3. Monocytosis at the time of diagnosis has a negative prognostic impact in myelodysplastic syndromes with less than 5% bone marrow blasts
4. Therapy-related myeloid neoplasms following treatment for multiple myeloma—a single center analysis
5. The WHO 2016 diagnostic criteria for Acute Myeloid leukemia with myelodysplasia related changes (AML-MRC) produce a very heterogeneous entity: A retrospective analysis of the FAB subtype RAEB-T
6. Aktuelle Entwicklungen in der interdisziplinären Krebstherapie
7. Myelodysplastische Syndrome: Diagnostik und Therapie
8. Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification—an approach to classification of patients with t-MDS
9. Diagnostik und Therapie der chronischen myelomonozytären Leukämie im Jahr 2020
10. Analysis of the impact of adherence to guidelines and expert advice in patients with myelodysplastic syndromes
11. Erratum zu: Diagnostik und Therapie der chronischen myelomonozytären Leukämie im Jahr 2020
12. Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials
13. The IPSS-R has prognostic impact in untreated patients with MDS del(5q)
14. Myelodysplastic syndromes without peripheral monocytosis but with evidence of marrow monocytosis share clinical and molecular characteristics with CMML
15. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: IMPROVED PROGNOSIS OF PATIENTS WITH MDS OVER FOUR DECADES: ANALYSIS FROM THE GERMAN MDS REGISTRY
16. Topic: AS04-MDS Biology and Pathogenesis/AS04d-Somatic mutations: TP53 ALLELIC STATE DID NOT INFLUENCE THE PROGNOSIS IN MYELODYSPLASTIC SYNDROMES (MDS) WITH 5Q DELETION
17. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: INTERMEDIATE RISK KARYOTYPE BY IPSS-R CAN BE SEPARATED INTO 5 PROGNOSTICALLY DISTINCT SUBGROUPS IN MDS PATIENTS
18. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: A STEP TOWARDS IDENTIFICATION AND CAUSAL INTERPRETATION OF THERAPY-RELATED MDS (T-MDS)
19. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: ACCELERATED FAILURE TIME MODELS AS A CLINICALLY PLAUSIBLE WAY TO DESCRIBE SURVIVAL IN MDS – AN ANALYSIS OF THE IWG-PM DATABASE
20. Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression): GENOMIC CLASSIFICATION OF MYELODYSPLASTIC SYNDROMES
21. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: COMPARISON OF PROGNOSTICATION BY IPSS-M, IPSS-R AND AIPSS-MDS IN THE CONTEXT OF LIMITED AVAILABILITY OF MOLECULAR DATA IN DAILY CLINICAL PRACTICE
22. Cause of death and excess mortality in patients with lower-risk myelodysplastic syndromes (MDS): A report from the European MDS registry.
23. Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes.
24. Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes
25. A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study
26. Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes
27. Determinants of low health-related quality of life in patients with myelodysplastic syndromes: EUMDS registry study
28. P095 - Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: ACCELERATED FAILURE TIME MODELS AS A CLINICALLY PLAUSIBLE WAY TO DESCRIBE SURVIVAL IN MDS – AN ANALYSIS OF THE IWG-PM DATABASE
29. P091 - Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: A STEP TOWARDS IDENTIFICATION AND CAUSAL INTERPRETATION OF THERAPY-RELATED MDS (T-MDS)
30. P094 - Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: INTERMEDIATE RISK KARYOTYPE BY IPSS-R CAN BE SEPARATED INTO 5 PROGNOSTICALLY DISTINCT SUBGROUPS IN MDS PATIENTS
31. P089 - Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: IMPROVED PROGNOSIS OF PATIENTS WITH MDS OVER FOUR DECADES: ANALYSIS FROM THE GERMAN MDS REGISTRY
32. P090 - Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: COMPARISON OF PROGNOSTICATION BY IPSS-M, IPSS-R AND AIPSS-MDS IN THE CONTEXT OF LIMITED AVAILABILITY OF MOLECULAR DATA IN DAILY CLINICAL PRACTICE
33. P052 - Topic: AS04-MDS Biology and Pathogenesis/AS04d-Somatic mutations: TP53 ALLELIC STATE DID NOT INFLUENCE THE PROGNOSIS IN MYELODYSPLASTIC SYNDROMES (MDS) WITH 5Q DELETION
34. P011 - Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression): GENOMIC CLASSIFICATION OF MYELODYSPLASTIC SYNDROMES
35. Refined medullary blast and white blood cell count based classification of chronic myelomonocytic leukemias
36. Monocytosis at the time of diagnosis has a negative prognostic impact in myelodysplastic syndromes with less than 5% bone marrow blasts
37. LUSPATERCEPT UTILIZATION PATTERNS IN LOWER-RISK MYELODYSPLASTIC SYNDROMES: FINDINGS FROM A MULTINATIONAL MEDICAL RECORD REVIEW STUDY
38. Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS)
39. Functional inhibition of mesenchymal stromal cells in acute myeloid leukemia
40. Myelodysplastische Syndrome
41. P772: PROGNOSTIC IMPACT OF DISEASE-RELATED RISK FACTORS AND TREATMENT APPROACHES IN PATIENTS WITH ADVANCED MYELODYSPLASTIC SYNDROMES (MDS)
42. P589: AGE AND AGE-ADAPTED RISK FACTORS HIGHLY INFLUENCE SURVIVAL PROBABILITY IN AML PATIENTS – A RETROSPECTIVE ANALYSIS
43. P771: PROGNOSTIC CHARACTERISTICS OF PATIENTS WITH MDS WITH ABERRATIONS OF CHROMOSOME 5. DATA FROM THE DÜSSELDORF MDS REGISTRY
44. S168: ERYTHROPOIETIN STIMULATION AGENTS SIGNIFICANTLY IMPROVES OUTCOME IN LOWER RISK MDS.
45. P783: SYSTEMIC THERAPY UTILIZATION AND HEMATOLOGIC OUTCOMES IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS): FINDINGS FROM A REAL-WORLD MEDICAL RECORD REVIEW STUDY IN THE US, UK, AND EUROPE (EU)
46. P448: PROGNOSTIC IMPACT OF SOMATIC CEBPA BZIP DOMAIN MUTATIONS IN ACUTE MYELOID LEUKEMIA
47. P532: ACUTE MYELOID LEUKEMIA (AML): UNICENTRIC REPORT ON 1029 PATIENTS DIAGNOSED IN TERTIAL REFERAL CENTER
48. Myelodysplastische Syndrome
49. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
50. Myelodysplastische Syndrome
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.